Optimization of Benzoxazinorifamycins to Minimize hPXR Activation for the Treatment of Tuberculosis and HIV Coinfection
Published by ACS Infectious Diseases on June 30, 2022
Tuberculosis is a leading infectious disease and cause of death. Folks with HIV are significantly more at-risk. Between 2 back-to-back papers, Dr. George Garcia designed and tested 52 benzoxazinorifamycins in hopes of developing a more effective treatment.